Latest KFF Health News Stories
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Oklahoma’s ‘Precedent-Setting’ Suit Puts Opioid Drugmakers On Trial
As states struggle to respond to the national drug crisis, officials around the country are watching Oklahoma. The state’s attorney general says opioid drugmakers helped ignite a health crisis that has killed thousands of residents.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Price Check On Drug Ads: Would Revealing Costs Help Patients Control Spending?
As part of his plan to tamp down drug pricing, President Donald Trump wants pharmaceutical companies to provide cost information in drug ads — just like side effects.
Addiction Medicine Mostly Prescribed To Whites, Even As Opioid Deaths Rose Among Blacks
A study looked at who gets Suboxone prescriptions and found that whites are almost 35 times more likely to get the addiction treatment than African Americans.
The Money And Politics Of Prescription Drugs: What You Need To Know
America spends about as much on prescription drugs as all the revenues of the three big car makers combined. Tracking where the money goes is hard. PolitiFact has some charts to help.
Drug Industry Patents Go Under Senate Judiciary Committee’s Microscope
During a hearing Tuesday, panel members focused on how drug companies have used patents to allegedly protect their competitive edge and profits.
Is Insulin’s High Cost Keeping Diabetes Patients From Taking Their Medicine?
An estimated 1.25 million Americans have Type 1 diabetes and cannot live without insulin. Sen. Kamala Harris’ claim that 1 in 4 diabetes patients cannot afford their insulin is a shockingly high number, so we decided to dig into the sparse data.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Klobuchar Wants To Stop ‘Pay-For-Delay’ Deals That Keep Drug Prices High
It’s as shady as it sounds.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Mulvaney: Trump Brought Down Drug Prices For The First Time In 50 Years
It’s “within spitting distance of something that’s true,” said one health economist. But our fact check found it wasn’t quite there.
The Blame Game: Everyone And No One Is Raising Insulin Prices
During Wednesday’s House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade’s 300% price increase, frustrating congressional representatives.
Can Someone Tell Me What A PBM Does?
The Senate Finance Committee’s third drug-pricing hearing focused on pharmacy benefit managers, and was more of a fact-finding mission on how these companies operate than a debate about policy proposals.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Doughnut Hole Is Gone, But Medicare’s Uncapped Drug Costs Still Bite Into Budgets
Beneficiaries pay 25 percent of the price of their brand-name drugs until they reach $5,100 in out-of-pocket costs. After that, their obligation drops to 5 percent. But it never disappears.
